The patient Layla Richards was expected to die from acute lymphoblastic leukemia, however by doctors receiving the permission from her parents and Cellectis she was the first person to receive the treatment. As a result, doctors and researchers will be able to see how effective this treatment is for humans. As of now Layla is in remission with no signs of leukemia in her blood or bone. The advancement of genome editing has led to the ability to make a treatment that is “universal” also known as non personalized where doctors can use T cells from a healthy donor that are modified to target leukemia cells , which can be placed into cancer patients. Cellectis the Biotechnology Company has also had other advancements in genome editing, such as using molecular scissors to make alterations to DNA. Although, this new treatment will not enter clinical trials till next year in the future this new treatment may provide more options for cancer patients. Layla’s medical case is evidence enough that this cell therapy may actual work. Although, it will take a long time before Cellectis therapy reaches the market if it does it will be cost efficient and a time